Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 7/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | STK4 | Q13043 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311677 | 1.00 | MARK3 (0.39) | MARK3SYKCTSCSTK4PTK2 | |
| SCHEMBL3374043 | 0.90 | MAPT (0.36) | SYKMAPTRAB9AEGFR | |
| SCHEMBL13311680 | 0.90 | MAPT (0.36) | SYKMAPTRAB9AEGFR | |
| SCHEMBL13421412 | 0.86 | IDH1 (0.39) | MARK3CTSCSTK4RAB9AMAPK10 | |
| SCHEMBL3448982 | 0.82 | TYRO3 (0.35) | SYKMAPTRAB9AEGFRITK | |
| SCHEMBL3450532 | 0.82 | TYRO3 (0.35) | SYKMAPTRAB9AEGFRITK | |
| SCHEMBL3448980 | 0.82 | TYRO3 (0.35) | SYKMAPTRAB9AEGFRITK | |
| SCHEMBL13311687 | 0.78 | SYK (0.38) | SYKMAPTRAB9AEGFR | |
| SCHEMBL3377742 | 0.78 | SYK (0.38) | SYKMAPTRAB9AEGFR | |
| SCHEMBL13311695 | 0.78 | SYK (0.38) | SYKMAPTRAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | MARK3 4802/4885SYK 804/4885CTSC 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.